Baseline Imaging Derived Predictive Factors of Response Following [¹⁷⁷Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis.

ABSTRACT: Earlier studies have mostly identified pre-therapeutic clinical and laboratory parameters for the prediction of treatment response to [¹⁷⁷Lu]Lu-PSMA-617 in metastatic castration resistant prostate cancer patients (mCRPC). The current study investigated whether imaging-derived factors on baseline [⁶⁸Ga]Ga-PSMA-11 PET/CT can potentially predict the response after two cycles of [¹⁷⁷Lu]Lu-PSMA-617 treatment, in a lesion- and patient-based analysis in men with mCRPC. Included patients had histologically proven mCRPC and a [⁶⁸Ga]Ga-PSMA-11 PET/CT before and after two cycles of [¹⁷⁷Lu]Lu-PSMA-617 treatment. The imaging-based response was evaluated on lesion-level (standardized uptake value (SUV) reduction) and patient-level (total lesion PSMA

SUBMITTER: van der Sar ECA 

PROVIDER: S-EPMC9313142 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature